*All numbers are in the form of Mean ± SD unless stated otherwise; †Changes compared to baseline.AAO, American Academy of Ophthalmology; Afl, aflibercept; Bev, bevacizumab; CATT, comparison of AMD treatment trial; CMT, central macular thickness; IQR, interquartile range; IRIS registry, Intelligent Research in Sight registry; IVAN, inhibit VEGF in age-related choroidal neovascularization trial; PrONTO, prospective OCT imaging of patients with neovascular AMD treated with intraocular ranibizumab; Ran, Ranibizumab. This evidence concerns the gene VEGFA and age-related macular degeneration.